

CURRICULUM VITAE

12/2015

BARRY A. HENDIN, M.D.

Address: 5090 N. 40th St. Suite 250
Phoenix, AZ 85018

EDUCATION

A.B. 1964 - Washington University
M.D. 1968 - Washington University Medical School

CLINICAL APPOINTMENTS

Intern, St. Louis Jewish Hospital, 1968-1969
Resident & Fellow, Barnes Hospital, 1969-1972 (including rotating chief residency)
Acting Chief of Neurology Service, St. Louis City Hospital, 1972
Chief of Neurology Service, Wright-Patterson, AFB, 1972-1974
Chief of Neurology, Good Samaritan Hospital, 1979-2014
Co-Director, EEG Laboratory, Good Samaritan Hospital, 1979-2014
Co-Director, EEG Laboratory, Phoenix Baptist Hospital, 1976-1991
Co-Director, EEG Laboratory, Columbia Medical Center, 1993-1999
Chairman, Division of Neurosciences, Good Samaritan Hospital, 1991-1992
Chairman, Credentials Committee, Good Samaritan Hospital, 1993-1995
Chairman, Advisory Committee, Good Samaritan Hospital, 1993-1995
Vice Chief of Staff, Good Samaritan Hospital, 1993-1995
Executive Committee, Good Samaritan Hospital, 1993-2014
Co-Director, Multiple Sclerosis Fellowship Program, Barrow Neurological Institute - 2013
Partners in MS Care, National Multiple Sclerosis Society – 2014 - Present
Director, Multiple Sclerosis Clinic, Banner University Medical Center – 2015 - Present

ACADEMIC APPOINTMENTS

Assistant (Medicine), Washington University Medical School, 1968-1969
Assistant (Neurology), Washington University Medical School, 1969-1972
Instructor (Neurology), Washington University Medical School, 1972
Clinical Associate (Neurology), University of Arizona Medical School, 1985-1987
Clinical Lecturer (Neurology), University of Arizona Medical School, 1988-1995
Consultant/Lecturer, Chigasaki Tokushukai Medical Center, Japan, November 1990
Clinical Professor of Neurology, University of Arizona Medical School, 1995-present

OTHER APPOINTMENTS

Governor's Council on Spinal and Head Injury, 1993 -1995
Member, Board of Directors, Samaritan Health Services, 1995-1999
 Chairman, Science & Technology Committee
 Audit Committee
 Finance Committee
 Development Committee
 Governance Committee
 Executive Committee
Member, Board of Directors Banner Health System, 1999 - 2014
 Chairman, 2009 - 2011
 Vice Chairman, 2007 - 2009
 Executive Committee 1999 -2006; 2007 - 2014
 Nominating Committee, 2009 - 2014
 Corporate Strategy Committee, 1999 - 2014
 Chairman, 2007-2007
 Human Resources Committee 1999 - 2001
 Care, Management & Quality Committee 1999 - 2014
 Vice Chairman, 2007
 Finance Committee 1999 - 2014
 Strategic Planning Committee 1999 - 2001
 Clinical Quality & Innovation Committee 1999 - 2014
 Vice Chairman 2001
American Heart Association, Phoenix Board Member, 2000
Arizona Commission on Medical Education and Research, Task Force, 2006 -2007
National Multiple Sclerosis Society
 Clinical Advisory Committee 2003 – Present
 Board of Directors 2007 - Present
Committee member, House Ad Hoc Committee for Multiple Sclerosis Awareness and
Education, Arizona House of Representatives - 2015 - Present

LICENSURE

Missouri, 1968 (inactive) Arizona, 1974 (License #8398)

HONORS AND AWARDS

Co-Editor, Neurologic Section, Arizona Medicine, 1975-1983
Outstanding Teacher Award, USAF Medical Center, Wright Patterson 1972-1973
Teacher of the Year Award, Good Samaritan Hospital, 1978-1979
Teacher of the Year Award, Good Samaritan Hospital, 1985-1986
Teacher of the Year Award, Good Samaritan Hospital, 1987-1988
Attending Physician of the Year Award, Barrow Neurological Institute, 1983-1984
Dean's List for Excellence in Teaching in the Clinical Sciences, University of AZ, 1999
Dean's List for Excellence in Teaching in the Clinical Sciences, University of AZ, 2001
Recognition of Excellence in Teaching the Clinical Sciences, University of Arizona, 2007

HONORS AND AWARDS (CONT.)

Honorary Alumnus Award, University of Arizona
Art of Caring Award, Global Caring Nurses Foundation, 2008
Nominee, Clinical Sciences Teacher of the Year, University of Arizona, 2007-2008
Health Professional of the Year, National Multiple Sclerosis Society, Arizona Chapter,
2007 & 2009

SOCIETY MEMBERSHIPS

American Academy of Neurology, Fellow Member
Education Committee/Annual Meeting Subcommittee 1990-1997
Maricopa County Medical Society
Arizona Medical Association
Arizona Neurological Society
Board of Directors 2005-2007

MILITARY SERVICE

Major, USAF, MC - Active Duty, September 1972 - September 1974
Chief, Neurology Service, USAF Medical Center, Wright-Patterson

BOARD CERTIFICATION

Neurology - American Board of Psychiatry & Neurology - March 15, 1975
Board Examiner, American Board of Psychiatry & Neurology, 1975-2009

PUBLICATIONS

1. Hahn TJ, Haddad JG, Hendin BA. Effect of chronic anticonvulsant therapy on serum 25-OH vitamin D levels. *Clinical Research* 1972; 20:238
2. Hahn TJ, Hendin BA, Shoop CR, Haddad CG. Effect of anticonvulsant therapy on serum 25-Hydroxycholecalciferol in adults. *New Eng Jour of Med* 1972; 297:900-904
3. Hendin BA, DeVivo DC, Torac R, Lell M, Regab AH, Vieggi TJ. CNS parenchymatous degeneration in childhood leukemia. Presented at the American Society of Clinical Oncology, April 1972
4. Hendin BA, Hahn TJ, Haddad JG. Effect of anticonvulsant therapy on anticonvulsant vitamin D levels. Presented at the Society of Air Force Physicians, February 1973
5. Hendin BA, DeVivo DC, Torac R, Lell ME, Regab AH, Vietti TJ. Parenchymous degeneration of the central nervous system in childhood leukemia. *Cancer* 1974; 33:468-482
6. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin's disease - an immunological study. *Arch of Neurol* 1976; 33:616-661
7. Hendin BA. The remote effects of cancer on the nervous system: cerebellar degeneration. *AZ Med* 1977; 34:462-463

PUBLICATIONS (CONT.)

8. Hahn TJ, Hendin BA, Haddad JG. Serum 25-Hydroxycholecalciferol levels and bone mass in children on clinical anticonvulsant therapy. *New Eng Jour of Med* 1975; 272:550-554
9. Hendin BA, Schaffert A. Tetanus. *Samaritan Medicine*. 1984; 29-32
10. Hendin BA. CPC: Herpes zoster. *Samaritan Medicine* 1985; 2:19
11. Yudell A, Hendin BA, Tamm HS, Guidry J. Coccidioidal meningitis narcotic amphotericin B therapy. *Arch Internal Med* 1988; 148:985-986
12. Clark W, Coull B, Hendin BA, et al. Randomized trial of Cervene a kappa receptor-selective opioid antagonist, in acute ischemic stroke (poster). Presented at American Academy of Neurology Meeting, Seattle, Washington, 1995
13. Clark W, Coull B, Hendin BA, et al. Randomized trial of Cervene, a kappa receptor-selective opioid antagonist, in acute ischemic stroke. *Journal of Stroke and Cerebrovascular Disease*; Vol 6, No. 1:35-40, 1996
14. Miravalle A, Hendin BA, Vollmer T, Kala M. Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis. *Clinical Medicine Insights: Therapeutics* 2011;3 151-158
15. Svenningsson A, Hendin BA. Clinical, biochemical and imaging parameters that may be predictive of high disease activity, rapid progression or increased disability in multiple sclerosis. *Citation European Neurological Review* 2012;7 (Supplement 2)
16. Prigatano GP, Hendin BA, Heiserman JE. Denial or unawareness of cog deficit associated with multiple sclerosis? A case Report. *Journal of Clinical and Experimental Neuropsychology*, DOI: 10.1080/13803395.2014.890700
17. Current practice patterns of MS relapse management among MS specialists in the United States: survey results of the MS relapse practice patterns project. Q Khan , R Berkovich, B Hendin, A Javed, A Miller, C Tornatore. ECTRIMS 2015 Poster Presentation .
18. The Delphi Method on Peginterferon Beta-1 Injection Site Reactions and Management Strategies in the Relapsing-Remitting Multiple Sclerosis ALLOW Study. DeRen Huang, Sibyl Wray, Barry Hendin, Robert Naismith, Sheri Rosenblatt, Brian Werneburg, Javier Zambrano. ECTRIMS 2015 and PACTRIMS 2015 Poster.
19. - ALLOW - A Phase 3b Trial Characterising Flu-like Symptoms in Patients Transitioning to Pegylated Interferon Beta-1a: Interim Analysis of all Patients. Robert T. Naismith, Barry Hendin, Sibyl Wray, Xiaojun You, Guido Sabatella, Javier Zambrano. ECTRIMS 2015 and PACTRIMS 2015 Poster.
20. Use of patient case scenarios to assess current practice patterns of MS relapse assessment and treatment among MS Specialists in the United States. Adil Javed, Regina Berkovich, Barry Hendin, Aaron Miller, Carlo Tornatore. ECTRIMS 2015 Poster.

MAJOR PRESENTATIONS

American College of Physicians. Management of Cerebrovascular Disease, November 1984

American College of Physicians. Management of Cerebrovascular Disease, November 1985

American College of Physicians. Management of Cerebrovascular Disease, November 1986

Arizona Medical Association. Prevention of Cerebrovascular Disease, June 1987

American College of Physicians. Management of Cerebrovascular Disease, November 1988

Arizona Academy of Family Physicians. Management of Cerebrovascular Disease, Current Management of Epilepsy, June 1989

American College of Physicians. Management of Cerebrovascular Disease, November 1989

American College of Physicians. Management of Cerebrovascular Disease, November 1990

American College of Physicians. Management of Cerebrovascular Disease, November 1991

American College of Physicians. Recent Advances in Therapeutics, November 1992

American College of Physicians. Recent Advances in Therapeutics, November 1993

American College of Physicians. Recent Advances in Therapeutics, November 1995

American College of Physicians. Recent Advances in Therapeutics, November 1997

American College of Physicians. Recent Advances in Therapeutics, November 1998

American College of Physicians. Management of Stroke and Cerebrovascular Disease, November 1999

American College of Physicians. Brain Attack, November 2000

American College of Physicians. Stroke Update. November 2001

American College of Physicians. Stroke Therapy 2002. Mayo Clinic Scottsdale, October 2002

MAJOR PRESENTATIONS (CONT.)

American College of Physicians. Neurology for the Internist. Update in Clinical Medicine. Scottsdale, AZ, November 7, 2002

American College of Physicians. Neurology Update. Scottsdale, Arizona, November 14, 2003

Instituto Nacional de Neurologia y Neurocirugia. Le Cefalia (cephalgia), Mexico City, July 1993

Kings County Family Practice Society. Recent Advances in Stroke Therapy, April 1994

San Diego Neurologic Society. New Antiepileptic Medications, May 1994

Stroke Update 1994, St. Joseph's Hospital. Acute Stroke Treatment - New Trials and Principles, September 1994

Instituto Nacional de Neurologia y Neurocirugia. El Diagnostico y Tratamiento de la Cefalea en el Primer Nivel de Atencion. La Emfermidad Cerebro Vascular en el Primer Nivel De Atencion, Mexico City, July 1995

Third Annual Neurosciences Symposium, Good Samaritan Regional Medical Center (Phoenix, AZ). Current Medical Advances in Neurological Diseases, June 1998

Mayo Clinic Scottsdale Neuro Grand Rounds. Current Advances in Neurologic Diseases, June 10, 1998

Management of Epilepsy: Consensus Conference on Current Clinical Practice (participant), June 17, 1998, Huatulco, Mexico. Published in Supplement 4 to Neurology, Volume 51, No 5, November 1998

Neurology Grand Rounds, University of New Mexico, Albuquerque, New Mexico. June 10, 1999

American Heart Association. Clinical Management and Protocols for Stoke Patients. Phoenix, AZ, September 10, 1999

Treatment of Psychiatric and Neurologic Disorders Symposium. The Pathophysiology and Treatment of Neuropathic Pain Transmission. San Diego, CA, February 5, 2000

San Diego Academy of Family Physicians. Epilepsy. San Diego, CA, July 8, 2000

Neurology & Neurosurgery Grand Rounds, University of Arizona Health Sciences Center, Tucson, Arizona. Strategy in Headache Management. September 29, 2000

Neurology Grand Rounds, University of California, Irvine. Rational Sequencing of Antiepileptic Drugs 2003

MAJOR PRESENTATIONS (CONT.)

Nevada Academy of Family Physicians. Migraines. Reno, Nevada, May 1, 2003

Texas Academy of Family Physicians Migraine Symposium. Management of Migraine Headache. Austin, TX, October 18, 2003.

Nevada Academy of Family Physicians. Migraine. Every Minute Counts. Lake Tahoe, Nevada, February 1, 2005

Arizona Academy of Family Physicians. Migraine Update. March 2005

Update in Clinical Medicine. New Britain General Hospital. Update in Stroke/Cerebrovascular Disease. Scottsdale, Arizona, November 9, 2005

Mayo Clinic College of Medicine. 19th Annual Epilepsy Update. Scottsdale, Arizona, November 3, 2006

Neurology & Neurosurgery Grand Rounds, University of Arizona Health Sciences Center, Tucson, Arizona. Multiple Sclerosis Update. November 3, 2007

Sunrise Hospital & Medical Center. Advances in Clinical Neurology and Neurosurgery Update 2008: "Immunomodulatory Therapies for Multiple Sclerosis." Las Vegas, Nevada. March 26, 2008

Neurology & Neurosurgery Grand Rounds, University of Arizona Health Sciences Center, Tucson, Arizona. Multiple Sclerosis Update. August 27, 2010

Mayo Clinic MS Symposium. MS Symptomatic Therapies. Scottsdale, Arizona. March 5, 2011

Barrow Neurological Institute Multiple Sclerosis Symposium. Current Treatment Options for Multiple Sclerosis. April 12, 2014.

University of Gothenburg MS Clinic. Recent developments in MS. October 2015.

Arizona House of Representatives. Overview of current research on multiple sclerosis. November 17, 2015.

RESEARCH PROTOCOLS

Principal Investigator for the following:

Protocol # E301. DHE-45 Nasal Spray for headache
Protocol # GHBA-903. Sumatriptan for headache

RESEARCH PROTOCOLS (CONT.)

Protocol # IX-101-002. IV Nalmefene for stroke
Protocol # 303. Mentane HP 029 for Alzheimer's disease
Protocol # 945-090. Gabapentin for epileptic seizures
Protocol # 979-7. C1979 for Alzheimer's disease
Protocol # VGPR0098. Sabril for epileptic seizures
Protocol # VGPR0101. Sabril for epileptic seizures
Protocol # UB-IN-9. Lubeluzole for stroke
Protocol # IX-103-002. Nalmefene for stroke
Protocol # BMS 180048. CN115-025 for migraine
Protocol # M92-825. Tiagabine for seizures
Protocol # GHBA. Eldepryl for Parkinson's disease
Protocol # S2WA-3001. Naratriptan for migraine
Protocol # IX-104-002. Nalmefene for stroke
Protocol # 982-25-045. Fosphenytoin for stroke
Protocol # SB202026. 20206 for Alzheimer's disease
Protocol # 945-000-213. Neurontin for seizures
Protocol # 945-217. Neurontin for migraine
Protocol # SB220453. 220453 for migraine
Protocol # 105-133. Lamictal for seizures
Protocol # Lub-USA-6. Lubeluzole for stroke
Protocol # 3062K1-200-US. Fiblast for stroke
Protocol # 52WA4002. Naratriptan for migraine
Protocol # 202026/050 for Alzheimer's disease
Protocol # 1008-099/010. Pregabalin for seizures
Protocol # CN123-011. IV BMS 204352 for stroke
Protocol # IP302-016. Citocoline for stroke
Protocol # 1008-032/033. Pregabalin for low back pain
Protocol # 981-124 Atorvastatin for stroke/TIA
Protocol # AST02. ICOS HALT for stroke
Protocol # 30006. Lamictal comparison/menstrual abnormalities
Protocol # 0101. Rufinamide for seizures
Protocol # PRI-TOP-IN-28. Topamax for seizures
Protocol # ELET-071. Eletriptan for migraine
Protocol # GLY-30011. GAIN-ASIST for stroke
Protocol # LAM40091. Lamictal for seizures
Protocol # S2W40027. Naratriptan for menstrual migraine
Protocol # 872CL003. ARTIST MRI for stroke
Protocol # 872CL004. ARTIST + for stroke
Protocol # CCM9981A04. Comtan for Parkinson's disease
Protocol # BMS IM101-200 for multiple sclerosis
Protocol # Biogen C1802 for multiple sclerosis
Protocol # Astra Zeneca 311CVS/0022. Zomig Nasal Spray
Protocol # SUM40299. Imitrex for migraine headaches
Protocol # Charisma EFC4505. Plavix vs aspirin
Protocol # Fujisawa FK 506 for stroke.

RESEARCH PROTOCOLS (CONT.)

Protocol # XRP4563H/4001. Lovenox for stroke
Protocol # GSK 249417 for stroke
Protocol # GSK LAM40112. Lamictal for cognition
Protocol # GSK LAM40124. Lamictal for behavior
Protocol # Ilex-Campath for MS
Protocol # Berlex/MDS - MS study
Protocol # Biogen 1808 for multiple sclerosis
Protocol # Genentech. Rituxan for dermatomyositis
Protocol # ACT. Avonex/steroids for multiple sclerosis
Protocol # Teva 9013 for MS
Protocol # Teva NC100 for MS
Protocol # Pfizer Implement study for MS
Protocol # Genentech U2787g for MS
Protocol # Glaxo 101468/228 for Parkinson's disease
Protocol # Glaxo LAM100034 for partial seizure
Protocol # Glaxo LAM100036 for generalized seizure
Protocol # Ortho McNeil CAPSS272 for seizure
Protocol # Biogen Avonex for CIDP
Protocol # Glaxo 49653/461 for Alzheimer's
Protocol # Johnson & Johnson 333369EPY2003 for seizure
Protocol # Genentech RIM study for dermatomyositis
Protocol # Boehringer-Ingelheim - PROFESS for post-stroke
Protocol # Teva TNC GA MS 2004 01 ASSERT for MS
Protocol # Columbia University Selection for ALS
Protocol # T-GEN for ALS
Protocol # Teva PM028. NABS for MS
Protocol # Weintraub Palm Mag Device for Diabetic Neuropathy
Protocol # Biogen. Strata for MS
Protocol # Lilly HMDY for diabetic neuropathy
Protocol # Lilly F1J-US-HMEZ for diabetic neuropathy
Protocol # GSK AVA104617 for Alzheimer's disease
Protocol # Novartis FTY720D 2302 for MS
Protocol # Biogen 101MS 102 for MS
Protocol # Biogen 109 MS 301 for MS
Protocol # Lilly small fiber neuropathy
Protocol # BIOMS MBP8298-SP-03 for secondary progressive MS
Protocol # Biogen 101MS 402 for MS
Protocol # Teva Bravo for MS
Protocol # Lilly HMEF for MS
Protocol # Merck Musi Qo1 for MS
Protocol # Roche/Genentech ocrelizumab for MS
Protocol # MedImmune CP 151 for dermatomyositis/polymyositis
Protocol # David Saperstein - Lithium for inclusion body myositis
Protocol # Cytex Arimoclomol for ALS
Protocol # Mass General Ceftriaxone for ALS

RESEARCH PROTOCOLS (CONT.)

Protocol # T-GEN Tretinoin for ALS
Protocol # Schering-Plough TIMI 50 for post-stroke
Protocol # Genzyme MTAP Myozyme for Pompe
Protocol # J&J 333369 NPP 2002 for diabetic peripheral neuropathy
Protocol # Biogen 108 MS 302 for MS
Protocol # UCB N01276 for Epilepsy
Protocol # UCB N01315 for Epilepsy
Protocol # Biogen 109 MS 303 for MS
Protocol # Biogen 105 MS 301 for MS
Protocol # Lilly FIJ-US for MS
Protocol # Cytokinetics CY4021 for ALS
Protocol # Biogen 205 MS 301 for MS
Protocol # Novartis Gil EPOC
Protocol # Sanofi Teracles
Protocol # Biogen Prefer
Protocol # Roche Opera WA21093
Protocol # Roche Oratorio WA25046
Protocol # Biogen Esteem
Protocol # Biogen Synergy
Protocol # Novartis BAF
Protocol # Biogen ALLOW
Protocol # Teva ARPEGGIO
Protocol # Novartis Transition
Protocol # Novartis Assess

Co-Investigator for the following:

Protocol # Genzyme Aubagio Hair Thinning Project MS
Protocol # Sanofi TeriPRO IPS13567 MS
Protocol # Biogen 109MS5413 Tecfidera Study
Protocol # Serono Autoinjector Study
Protocol # Genzyme Switch Study